ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Song Wan
Martine Antoine
Anthony P.C. Yim
Jean-Louis Vincent
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wan, S.
Right arrow Articles by Vincent, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wan, S.
Right arrow Articles by Vincent, J.-L.

Ann Thorac Surg 1999;68:1230-1235
© 1999 The Society of Thoracic Surgeons

Original Articles

Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study

Song Wan, MD, PhDa, Jean-Louis LeClerc, MDa, Martine Antoine, MDa, Jean-Marie DeSmet, MDa, Anthony P.C. Yim, MDa, Jean-Louis Vincent, MD, PhDb

a Departments of Cardiac Surgery, University Hospital Erasme, Free University of Brussels, Brussels, Belgium
b Intensive Care, University Hospital Erasme, Free University of Brussels, Brussels, Belgium

Address reprint requests to Dr Wan, Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
e-mail: swan{at}cuhk.edu.hk

Background. The effects of heparin-coated (HC) circuits have been primarily investigated in routine cardiac operations with limited duration of cardiopulmonary bypass (CPB) and ischemia. Their benefits have not been conclusively proven but could be more significant when CPB and ischemic times are longer, such as during heart transplantation (HTx) or heart-lung transplantation (HLTx).

Methods. In a 22-month period, 29 patients undergoing HTx and HLTx were randomly divided into two groups using HC (Duraflo II, n = 14, 10 HTx and 4 HLTx) or uncoated but identical circuits (NHC group, n = 15, 10 HTx and 5 HLTx). All patients received full systemic heparinization (3 mg/kg) during CPB. Plasma endotoxin, interleukin (IL)-6, IL-8, IL-10, IL-12, and cardiac troponin-I were measured before heparin administration, immediately after aortic cross-clamping, 5, 30, 60, 90, 120 minutes, and 12 and 24 hours after aortic declamping. The intensive care unit (ICU) staff and the laboratory technologists were blinded as to the use of HC circuits.

Results. No statistically significant differences between groups were found with respect to all baseline values, duration of CPB and aortic cross-clamping, graft ischemic time, doses of heparin, postoperative blood loss and transfusion, peak lactate and creatine kinase-MB isoenzyme values, duration of mechanical ventilation, or length of ICU stay. One patient in each group died during the hospital stay. Patients in the HC group needed more protamine sulfate after CPB. Although endotoxin levels were similar in the two groups, significantly lower IL-6, IL-8, and IL-10 levels were observed 1 hour after aortic declamping in the HC group. The release of cardiac troponin-I was also significantly reduced in the HC group 12 and 24 hours after reperfusion.

Conclusions. The use of HC circuit limits both pro- and anti-inflammatory responses to CPB. It may also reduce myocardial injury after prolonged duration of CPB and ischemia.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
M. Ranucci, A. Balduini, A. Ditta, A. Boncilli, and S. Brozzi
A Systematic Review of Biocompatible Cardiopulmonary Bypass Circuits and Clinical Outcome
Ann. Thorac. Surg., April 1, 2009; 87(4): 1311 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. B. Blossom, A. J. Kallen, P. R. Patel, A. Elward, L. Robinson, G. Gao, R. Langer, K. M. Perkins, J. L. Jaeger, K. M. Kurkjian, et al.
Outbreak of Adverse Reactions Associated with Contaminated Heparin
N. Engl. J. Med., December 18, 2008; 359(25): 2674 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 Asian Cardiovasc. Thorac. Ann.Home page
E. M. Carvalho, E. A Gabriel, and T. A Salerno
Pulmonary Protection During Cardiac Surgery: Systematic Literature Review
Asian Cardiovasc Thorac Ann, December 1, 2008; 16(6): 503 - 507.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou
Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes
Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. E. Jessen
Pro: Heparin-Coated Circuits Should be Used for Cardiopulmonary Bypass
Anesth. Analg., December 1, 2006; 103(6): 1365 - 1369.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
R. Taneja and D. C. Cheng
Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures
Anesth. Analg., December 1, 2006; 103(6): 1370 - 1372.
[Full Text] [PDF]

Home page
 Asian Cardiovasc. Thorac. Ann.Home page
S. G Raja and G. D Dreyfus
Modulation of Systemic Inflammatory Response after Cardiac Surgery
Asian Cardiovasc Thorac Ann, December 1, 2005; 13(4): 382 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, and T. E. Mollnes
Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition
Ann. Thorac. Surg., July 1, 2004; 78(1): 38 - 44.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. Kubala, M. Ciz, J. Vondracek, J. Cerny, P. Nemec, P. Studenik, H. Cizova, and A. Lojek
Perioperative and postoperative course of cytokines and the metabolic activity of neutrophils in human cardiac operations and heart transplantation
J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1122 - 1129.
[Abstract] [Full Text]

Home page
 PerfusionHome page
H. I Flom-Halvorsen, E Ovrum, F Brosstad, G Tangen, M A. Ringdal, and R Oystese
Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction
Perfusion, September 1, 2002; 17(5): 339 - 345.
[Abstract] [PDF]

Home page
 ChestHome page
C. S.H. Ng, S. Wan, A. P.C. Yim, and A. A. Arifi
Pulmonary Dysfunction After Cardiac Surgery*
Chest, April 1, 2002; 121(4): 1269 - 1277.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. C. Stoica, M. Goddard, and S. R. Large
The endothelium in clinical cardiac transplantation
Ann. Thorac. Surg., March 1, 2002; 73(3): 1002 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
D. Paparella, T.M. Yau, and E. Young
Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update
Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 232 - 244.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
L.-C. Hsu
Heparin-coated cardiopulmonary bypass circuits: current status
Perfusion, September 1, 2001; 16(5): 417 - 428.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. P.C. Yim, S. Wan, T. W. Lee, and A. A. Arifi
VATS lobectomy reduces cytokine responses compared with conventional surgery
Ann. Thorac. Surg., July 1, 2000; 70(1): 243 - 247.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.